RECORD // Company

Structure Therapeutics Inc.

Formerly: ShouTi Inc.

Built 2026-11-22T04:59:18Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (3)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • STRUCTURE THERAPEUTICS USA INC. · Ct business · exact name match to 'Structure Therapeutics Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • STRUCTURE THERAPEUTICS USA INC. · Ny corps · exact name match to 'Structure Therapeutics Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001104659-26-124503

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-144,757,0003 months ended 2026-09-3010-Q2026-11-090001104659-26-1245032026-11-22 04:59 UTCReport an error
Cash and cash equivalents$222,033,000at 2026-09-3010-Q2026-11-090001104659-26-1245032026-11-22 04:59 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001888886
Ticker
GPCR
EIN
981480821
CUSIP
86366E106
Record ID
sx:sec:0001888886

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

32 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 04:59 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 04:59 UTCReport an error
State of incorporationE92026-11-16SEC EDGAR company profile2026-11-22 04:59 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 04:59 UTCReport an error
Business address601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO, CA, 940802026-11-16SEC EDGAR company profile2026-11-22 04:59 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 04:59 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-141,202,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 04:59 UTCReport an error
Total assets (at 2025-12-31)$1,583,918,0002025-12-3110-K, XBRL Assets2026-11-22 04:59 UTCReport an error
Stockholders' equity (at 2025-12-31)$1,516,377,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 04:59 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$799,623,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 04:59 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-222,199,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 04:59 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$3,614,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 04:59 UTCReport an error
Operating lease liabilities (at 2025-12-31)$6,487,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 04:59 UTCReport an error
Form D total offering amount (D filed 2022-01-10)$6,999,9172022-01-10D2026-11-22 04:59 UTCReport an error
Form D total amount sold (D filed 2022-01-10)$6,999,9172022-01-10D2026-11-22 04:59 UTCReport an error
Form D industry groupBiotechnology2022-01-10D2026-11-22 04:59 UTCReport an error
Form D revenue rangeDecline to Disclose2022-01-10D2026-11-22 04:59 UTCReport an error
Form D date of first sale2021-12-152022-01-10D2026-11-22 04:59 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-09)On November 9, 2026, Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the…2026-11-09SEC EDGAR 8-K 0001104659-26-124494 (text as filed, excerpt)2026-11-22 04:59 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-09-08)On September 8, 2026, Structure Therapeutics Inc. (the Company) issued a press release announcing positive topline clinical trial results across its oral small molecule amylin and GLP-1 programs for chronic weight management, including Phase 1/2a single ascending dose (SAD) results for ACCG-2671 (oral small molecule amylin receptor agonist) and 72-week results from the ACCESS open-label extension (OLE) study of aleniglipron (oral small molecule selective GLP-1 receptor agonist). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On September 8, 2026, the Company made available on its website an investor presentation to be shared with investors and…2026-09-08SEC EDGAR 8-K 0001104659-26-105688 (text as filed, excerpt)2026-11-22 04:59 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-09-08)ACCG-2671 (Oral Small Molecule DACRA): Phase 1 SAD Topline Clinical Trial Results On September 8, 2026, the Company reported positive topline data for ACCG-2671, an oral, non-peptide, small molecule dual amylin and calcitonin receptor agonist (DACRA), from the SAD portion of the Phase 1/2a clinical trial. The SAD portion evaluated the safety, tolerability, pharmacokinetics (PK) and exploratory pharmacodynamic (PD) effects of ACCG-2671 in 31 healthy adult participants without obesity. A wide range of doses were explored in this first-in-human study to, among other things, inform the appropriate starting dose and titration regimen for the multiple ascending dose (MAD) study. Participants…2026-09-08SEC EDGAR 8-K 0001104659-26-105688 (text as filed, excerpt)2026-11-22 04:59 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-06)On August 6, 2026, Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the second quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the…2026-08-06SEC EDGAR 8-K 0001104659-26-092017 (text as filed, excerpt)2026-11-22 04:59 UTCReport an error
Largest institutional holder #1 (13F as filed): FMR LLC$419,179,1232026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:59 UTCReport an error
Largest institutional holder #2 (13F as filed): WELLINGTON MANAGEMENT GROUP LLP$396,054,1692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:59 UTCReport an error
Largest institutional holder #3 (13F as filed): Avoro Capital Advisors LLC$351,836,6372026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:59 UTCReport an error
Largest institutional holder #4 (13F as filed): Jupiter Topco LLC$279,339,3832026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:59 UTCReport an error
Largest institutional holder #5 (13F as filed): Deep Track Capital, LP$254,399,6642026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:59 UTCReport an error
Largest institutional holder #6 (13F as filed): BVF INC/IL$180,697,3902026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:59 UTCReport an error
Largest institutional holder #7 (13F as filed): ORBIMED ADVISORS LLC$118,578,4982026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:59 UTCReport an error
Largest institutional holder #8 (13F as filed): PRINCIPAL FINANCIAL GROUP INC$94,070,2542026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:59 UTCReport an error
Largest institutional holder #9 (13F as filed): AMERICAN CENTURY COMPANIES INC$90,282,9562026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:59 UTCReport an error
Largest institutional holder #10 (13F as filed): RTW INVESTMENTS, LP$86,274,9012026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:59 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.